Positive review of the European Medicines Agency in the approval process of Biofrontera's BF-200 ALA

31-Jan-2011 - Germany

Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency (EMA) in the ongoing centralized approval process of BF-200 ALA for the treatment of actinic keratosis.

The "Committee for Medicinal Products for Human Use (CHMP)" provides applicants on day 120 of the centralized approval process with an intermediate opinion and the open questions of the agency. The opinion considers the expert reviews of the rapporteurs (see adhoc 16-12-2010) and additional questions of all other EU member states. In the approval process of BF-200 ALA for actinic keratosis no major objections were raised at this point that would seriously endanger the approval. The agency recommended approval under the provision that satisfactory responses are given to the list of questions.

Biofrontera plans to respond within the scheduled time frame. In the centralized approval process, to which BF-200 ALA is eligible due to its high level of innovation, the marketing authorization will be granted for all EU member states in a single step.

BF-200 ALA is a drug for the treatment of actinic keratosis, a form of superficial non-melanoma skin cancer. Large clinical trials demonstrated the excellent efficacy of the new medicinal product and its clear superiority over the most relevant marketed competitor product. Actinic keratosis constitutes a major medical problem with patient numbers constantly growing due to the demographic development and the increasing exposure to UV light. Every other consultation of dermatologists in the USA is already related to this disease. Biofrontera therefore foresees an enormous market potential for its new drug.

https://www.bionity.com/en/news/130530/positive-review-of-the-european-medicines-agency-in-the-approval-process-of-biofrontera-s-bf-200-ala.html